haloperidol - Page 1 | CARLAT PUBLISHING

Research Update

Neuroleptic Malignant Syndrome in Youth Is Rare, but Risk Peaks Early

July 1, 2026

Joshua Feder, MD.
Dr. Feder has no financial relationships with companies related to this material.

NMS is feared but poorly characterized in pediatric populations. A Medicaid cohort of 1.66 million young antipsychotic users now offers the clearest picture yet of when risk is highest and which combinations clinicians should watch most closely.

Research Update

Does Haloperidol Improve Hospitalization or Mortality in Delirium?

June 1, 2024

Jeremy Mills, DNP, PMHNP-BC

Jeremy Mills, DNP, PMHNP-BC. Dr. Mills has no financial relationships with companies related to this material.

Another trial questions the benefits of antipsychotics in delirium.

Medications to Rapidly Treat Psychotic Agitation

September 13, 2021

Daniel Carlat, MD

Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report.

Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How do you choose medications to calm an acutely psychotic and agitated patient? We'll tell you which ones are the safest and most effective.

Pros and Cons of Using Oxcarbazepine Over Carbamazepine

August 28, 2020

Does the limited research support that oxcarbazepine is a safer and more effective treatment for bipolar disorder than its FDA-approved cousin, carbamazepine? Here is an overview of the pros and cons from a previous article in The Carlat Psychiatry Report.Pros:Similar effectiveness as other mood stabilizers. In mania and mixed states,...